What's new in Interventional Cardiology

Nicola Ryan provides her take on the WARRIOR trial which was presented by Eileen Handberg at ACC.25 in Chicago.

The manuscript for this trial has not been published and all assumptions are based upon the presentation.

Join the PCR community as we commemorate a big year for EuroIntervention!

In this video, your peers share why they read EuroIntervention and how it impacts their daily practice.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Any coronary intervention can be compromised by an iatrogenic hydraulic dissection: find out how to manage it with dissection stenting!

Dear Colleagues, dear PCR Companions,

As we welcome a new year, it is the perfect time to reflect on what we achieved together over the past year—both as a celebration of our successes and as motivation to continue improving in the year ahead.

2024 was a record year...

DCBs have undergone extensive development to meet the challenges of minimizing restenosis and maintaining vessel patency. Unlike stents, DCBs deliver an antiproliferative drug directly to the arterial wall without leaving a permanent implant. This approach has proven effective in treating small-vessel disease, in-stent restenosis, and de...

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

View a snapshot of the results of these 3 trials presented in London: TRISCEND II, COMPARE-TAVI cohort B and the 30-day Outcomes of the TF J-VALVE for Chronic AR

Alessandro Sticchi provides his take on the OPTION Trial presented at AHA 2024 in Chicago.